Transcatheter Repair for Patients with Tricuspid Regurgitation (TRILUMINATE Pivotal)
Source: View publication →
In patients with symptomatic severe tricuspid regurgitation, transcatheter edge-to-edge repair was highly safe, effectively reduced regurgitation severity, and significantly improved quality of life compared to medical therapy, though it did not lower mortality or heart failure hospitalizations at 1 year.
Key Findings
Study Design
Study Limitations
Clinical Significance
TRILUMINATE Pivotal established that transcatheter edge-to-edge repair (TEER) is a safe and effective method for reducing severe tricuspid regurgitation, resulting in meaningful symptomatic and quality-of-life benefits for a patient population that traditionally lacked viable treatment options. However, the trial simultaneously sparked significant clinical debate regarding the value and cost-effectiveness of device therapies that dramatically improve patient-reported symptoms without modifying objective, long-term disease progression markers like survival or hospitalization.
Historical Context
Historically known as the 'forgotten valve,' the tricuspid valve has long lacked effective targeted treatment options. Patients with severe, isolated tricuspid regurgitation (TR) often develop right-sided heart failure, peripheral edema, and severe fatigue, but isolated surgical correction carries prohibitively high mortality rates, ranging from 8-10% in observational studies. Consequently, most patients have been managed conservatively with diuretics alone. Following the success of TEER for the mitral valve (demonstrated in the COAPT trial), TRILUMINATE Pivotal was designed as the first landmark randomized controlled trial to investigate a dedicated TEER device for the tricuspid valve (TriClip), successfully ushering in a new era of percutaneous interventions for right-sided structural heart disease.
Guided Discussion
High-yield insights from every perspective
How does severe tricuspid regurgitation lead to the symptoms that this study aimed to treat with TEER, and why might reducing regurgitation improve a patient's quality of life even if it does not immediately improve mortality?
Key Response
TR causes volume overload of the right ventricle, leading to systemic venous congestion resulting in edema, ascites, and fatigue. TEER reduces this backward flow, alleviating congestive symptoms and directly improving daily functioning via reduced venous pressure, even if underlying right ventricular remodeling prevents a short-term mortality benefit.
When evaluating a patient with severe symptomatic tricuspid regurgitation, what clinical criteria and imaging findings would make them an ideal candidate for transcatheter edge-to-edge repair over isolated medical therapy, considering the TRILUMINATE trial results?
Key Response
Residents must recognize that isolated severe TR refractory to diuretics is the target. Ideal candidates have favorable valve anatomy on TEE and right ventricles that are not yet irreversibly failed. Since TEER improves KCCQ scores but lacks hard outcome benefits, shared decision-making regarding symptom relief versus survival is crucial.
The TRILUMINATE trial demonstrated improved quality of life but no reduction in heart failure hospitalizations or mortality at 1 year. How does the concept of right ventricular-pulmonary artery (RV-PA) coupling influence these hard outcomes, and how should this guide patient selection for tricuspid TEER?
Key Response
Fellows should understand that late-stage TR often involves irreversible RV dysfunction and pulmonary hypertension (uncoupled RV-PA). Correcting TR removes the low-impedance pop-off into the RA, increasing RV afterload. In a failing RV, this can unmask severe RV failure, explaining the lack of mortality benefit and emphasizing the need to intervene before irreversible uncoupling occurs.
Given that TRILUMINATE primarily showed a benefit in quality of life without a 1-year mortality or hospitalization benefit, how do you incorporate these findings into shared decision-making with older, frail patients, and does a QoL-driven endpoint justify the procedural risk in your practice?
Key Response
Attendings must balance procedural risks, costs, and benefits. For frail, elderly populations with severe TR, significant improvement in QoL is often the most patient-centered goal. This trial validates TEER as a palliative strategy, shifting the paradigm from survival at all costs to maximizing functional status in a difficult-to-treat demographic.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The TRILUMINATE trial relied heavily on patient-reported quality of life (KCCQ) to drive its hierarchical composite endpoint. In an unblinded device trial where patients know they received a novel intervention, how does the placebo effect threaten the validity of this subjective endpoint, and what trial design modifications could mitigate this bias?
Key Response
Without a sham procedure control, unblinded patients receiving an invasive, novel device are highly susceptible to the placebo effect, artificially inflating self-reported QoL metrics. A sham-controlled design would be required to definitively prove the QoL benefit is purely from hemodynamic improvement rather than psychological expectation.
TRILUMINATE utilized a hierarchical composite endpoint analyzed via the Finkelstein-Schoenfeld method (win ratio), driven almost entirely by the KCCQ score. As an editor, what are the inherent risks of publishing trials where soft endpoints dominate a composite win ratio, and how does this affect clinical interpretation?
Key Response
The win ratio hierarchically evaluates death, HF hospitalization, and KCCQ. Since TEER did not improve the first two, the wins were generated at the lowest tier. Editors must scrutinize whether masking negative hard outcomes behind heavily weighted subjective improvements misleads readers, making transparent reporting of the win ratio breakdown paramount.
The 2020 ACC/AHA Valvular Heart Disease guidelines give limited recommendations for transcatheter tricuspid interventions. Based on the TRILUMINATE trial demonstrating safety and QoL improvement but no mortality benefit, what specific Class of Recommendation and Level of Evidence should be proposed for tricuspid TEER?
Key Response
Current guidelines relegate transcatheter TR interventions to carefully selected patients (Class IIb). With TRILUMINATE providing Level of Evidence B-R, the committee would likely upgrade TEER to a Class IIa recommendation specifically for symptom improvement in highly symptomatic, severe TR patients on optimal medical therapy who are high risk for surgery.
Clinical Landscape
Noteworthy Related Trials
EVEREST II Trial
Tested
Percutaneous edge-to-edge mitral valve repair (MitraClip)
Population
Patients with moderate-to-severe or severe mitral regurgitation
Comparator
Surgical mitral valve repair or replacement
Endpoint
Composite of freedom from death, surgery for valve dysfunction, and grade 3+ or 4+ regurgitation at 12 months
COAPT Trial
Tested
Transcatheter edge-to-edge repair (MitraClip) plus medical therapy
Population
Patients with heart failure and severe secondary mitral regurgitation
Comparator
Guideline-directed medical therapy alone
Endpoint
All-cause hospitalizations for heart failure within 24 months
TriValve Registry Matched Cohort
Tested
Transcatheter tricuspid valve intervention (predominantly TEER)
Population
Patients with severe symptomatic tricuspid regurgitation
Comparator
Medical therapy alone (propensity-matched)
Endpoint
Composite of all-cause mortality and heart failure hospitalization at 1 year
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis